Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate
Denosumab May Help Prevent Bone Loss
Past Highlights
Results:
1 -5 of 5
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
10/11/2008
 
First Published:
3/17/2006
1.
Phase I/II Study of Motexafin Gadolinium Given Concurrently With Temozolomide and Fractionated Radiotherapy in Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme or Gliosarcoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Active
18 and over
NCI
RTOG-0513
RTOG-0513, NCT00305864
Last Modified:
10/17/2008
 
First Published:
10/6/2006
2.
Phase II Study of Motexafin Gadolinium and Involved-Field Radiotherapy in Pediatric Patients With Intrinsic Pontine Glioma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
21 and under at diagnosis
NCI
COG-ACNS0222
ACNS0222, NCT00387790
Last Modified:
5/9/2008
 
First Published:
8/3/2007
3.
Phase II Study of Concurrent and Adjuvant Temozolomide With Radiotherapy in Young Patients With Diffuse Pontine Gliomas
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Diagnostic, Supportive care, Treatment
Active
2 to 21
Other
CCLG-CNS-2007-04
CNS 2007 04, EU-20746, EUDRACT-2007-001768-60, NCT00514397
First Published:
7/15/2008
4.
Phase II Pilot Study of Neoadjuvant Sunitinib Malate Followed by Cytoreductive Nephrectomy and Adjuvant Sunitinib Malate in Patients With Stage IV Renal Cell Carcinoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Biomarker/Laboratory analysis, Diagnostic, Treatment
Active
18 and over
NCI, Pharmaceutical / Industry
UPCC-10807
UPCC 10807, PFIZER-807184, NCT00717587
First Published:
8/12/2008
5.
Phase II Pilot Study of Motexafin Gadolinium Combined With High-Dose Methotrexate-Based Chemotherapy, Rituximab, and Whole-Brain Radiotherapy in Patients With Newly Diagnosed Primary Central Nervous System Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Approved-not yet active
Over 18
NCI, Pharmaceutical / Industry
NU-05H7
NU 05H7, PCI-P-NU-05H7, NCT00734773
Select All on One Page
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute